as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 25 Sep 2026
₹599.3
Change
+1.8 (0.3%)
Open
₹602.35
Prev. Close
₹597.5
Day High
₹619.0
Day Low
₹594.6
Volume Analysis
Traded
151,067
Delivered
50,820
Delivery %
33.64%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (34.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (24.1%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹638.4 | ₹628.7 | ₹614.0 | ₹604.3 | ₹589.6 | ₹579.9 | ₹565.2 |
| Fibonacci | ₹628.7 | ₹619.38 | ₹613.62 | ₹604.3 | ₹594.98 | ₹589.22 | ₹579.9 |
| Camarilla | ₹606.01 | ₹603.77 | ₹601.54 | ₹604.3 | ₹597.06 | ₹594.83 | ₹592.59 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-0.37%
1 Week
-2.72%
1 Month
-2.98%
3 Months
+2.0%
6 Months
+46.82%
1 Year
-17.75%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹126.83
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
17.22%
Net margin 18.54% × asset turnover 0.72x × equity multiplier 1.29x
Company Overview
Sector
Healthcare
Market Cap
₹2,679 Cr
P/E (TTM)
44.1
ROE
13.5%
Book Value
₹77.2
Face Value
₹2.0
Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.
TopFund Analysis
Vimta Labs Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 59/100. The strongest factor is Financial Strength (100/100), while Valuation (4/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (34.0%); promoter holding is falling. Strong 3-year EPS growth (24.1%).
TopFund Score — Fundamentals Quality
59/100 — AverageData confidence: 77/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 27 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- −Stock is trading at 7.76 times its book value
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Allotment of Employee Stock Options under "Vimta Labs Employee Stock Option Plan 2021".
Vimta Labs schedules analyst and institutional investor meet on 08.09.2026.
CARE Ratings reaffirmed Vimta Labs’ bank facilities at CARE A; Stable and CARE A1 on 02 September 2026.
Vimta Labs says share volume spike is due to market factors, with no undisclosed information.
Exchange has sought clarification from Vimta Labs Ltd on September 01, 2026, with reference to Movement in Volume.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 67 | 74 | 79 | 80 | 77 | 82 | 83 | 66 | 75 | 80 | 75 | 85 | 90 |
| Expenses + | 47 | 51 | 55 | 54 | 56 | 58 | 59 | 48 | 51 | 55 | 49 | 55 | 57 |
| Operating Profit | 21 | 23 | 24 | 25 | 21 | 24 | 25 | 17 | 24 | 24 | 26 | 30 | 33 |
| OPM % | 31.0% | 31.0% | 30.0% | 32.0% | 28.0% | 30.0% | 30.0% | 27.0% | 32.0% | 31.0% | 35.0% | 35.0% | 37.0% |
| Other Income + | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | -1 | 0 | -1 | -1 | 5 |
| Interest | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 |
| Depreciation | 6 | 7 | 7 | 8 | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 10 |
| Profit before tax | 15 | 16 | 17 | 18 | 14 | 17 | 16 | 8 | 14 | 16 | 17 | 20 | 28 |
| Tax % | 25.0% | 27.0% | 28.0% | 26.0% | 27.0% | 23.0% | 25.0% | 25.0% | 25.0% | 24.0% | 26.0% | 24.0% | 23.0% |
| Net Profit + | 12 | 12 | 12 | 13 | 10 | 13 | 12 | 6 | 10 | 12 | 12 | 15 | 22 |
| EPS in Rs | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 1 | 2 | 3 | 3 | 3 | 5 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|
| Sales + | 181 | 211 | 278 | 318 | 318 | 329 |
| Expenses + | 151 | 158 | 198 | 223 | 231 | 216 |
| Operating Profit | 30 | 53 | 80 | 95 | 87 | 113 |
| OPM % | 17.0% | 25.0% | 29.0% | 30.0% | 27.0% | 34.0% |
| Other Income + | 3 | 1 | 0 | 3 | 4 | 4 |
| Interest | 4 | 2 | 2 | 3 | 2 | 2 |
| Depreciation | 21 | 23 | 23 | 31 | 34 | 34 |
| Profit before tax | 8 | 29 | 56 | 65 | 54 | 81 |
| Tax % | 17.0% | 25.0% | 26.0% | 26.0% | 25.0% | — |
| Net Profit + | 7 | 21 | 41 | 48 | 41 | 61 |
| EPS in Rs | 2 | 5 | 9 | 11 | 9 | 14 |
| Dividend Payout % | 0.0% | 21.0% | 11.0% | 9.0% | 11.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Reserves | 168 | 190 | 230 | 277 | 315 | 338 |
| Borrowings + | 33 | 30 | 19 | 15 | 19 | 12 |
| Other Liabilities + | 40 | 50 | 54 | 65 | 61 | 86 |
| Total Liabilities | 246 | 274 | 307 | 362 | 400 | 440 |
| Fixed Assets + | 138 | 135 | 169 | 175 | 171 | 183 |
| CWIP | 2 | 17 | 0 | 12 | 59 | 75 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 106 | 122 | 138 | 175 | 170 | 183 |
| Total Assets | 246 | 274 | 307 | 362 | 400 | 440 |
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 24 | 37 | 59 | 88 | 61 |
| Cash from Investing Activity + | -21 | -32 | -38 | -57 | -76 |
| Cash from Financing Activity + | -1 | -5 | -17 | -11 | -2 |
| Net Cash Flow | 3 | 1 | 5 | 20 | -17 |
| CFO/OP | 102 | 84 | 94 | 106 | 88 |
| Free Cash Flow | 9 | 4 | 20 | 38 | -14 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 58.75% | 58.65% | 56.45% | 56.45% | 59.8% | 58.28% | 58.2% | 58.42% | 58.8% | 59.4% | 59.12% | 59.55% |
| Promoters | 37.0% | 36.98% | 36.92% | 36.89% | 36.89% | 36.76% | 36.7% | 36.67% | 35.99% | 35.89% | 35.85% | 35.66% |
| FII | 2.74% | 2.88% | 5.13% | 5.16% | 3.31% | 3.81% | 3.66% | 3.49% | 4.33% | 4.59% | 4.89% | 4.41% |
| DII | 1.5% | 1.49% | 1.5% | 1.49% | 0.0% | 1.15% | 1.43% | 1.42% | 0.87% | 0.11% | 0.13% | 0.37% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Vimta Labs Limited (this stock) | 2,679 | 44.1 | 7.76 | 13.5% |
| Dishman Carbo Amcis Ltd | 2,718 | 150.0 | 0.41 | 1.58% |
| Hikal Limited | 2,731 | 64.4 | 2.28 | 2.21% |
| Sakar Healthcare Limited | 2,527 | 70.0 | 7.78 | 9.99% |
| Shukra Pharmaceuticals L | 2,465 | 72.6 | 27.27 | 28.9% |
| Fischer Medical Venture L | 2,401 | 98.1 | 5.85 | 8.91% |
| Beta Drugs Limited | 2,400 | 52.6 | 8.98 | 18.8% |
Which Mutual Funds Hold Vimta Labs Limited?
Frequently Asked Questions about Vimta Labs Limited
Vimta Labs Limited (VIMTALABS) closed at ₹599.3 on NSE on 25 September 2026, up 1.8 (0.3%) from the previous close.
Vimta Labs Limited trades on the NSE (National Stock Exchange of India) under the symbol VIMTALABS.
Vimta Labs Limited has a trailing twelve-month P/E (price-to-earnings) ratio of 44.1.
Vimta Labs Limited has a dividend yield of 0.33%.
Vimta Labs Limited's 52-week high is ₹775.0 and its 52-week low is ₹376.0.
Vimta Labs Limited has a market capitalisation of ₹2,679 crore.
Vimta Labs Limited has a TopFund Quality Score of 59/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Vimta Labs Limited?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.